Olmesar-H

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olmesar-H

Quick Facts

Property Description
Active Ingredients Olmesartan Medoxomil, Hydrochlorothiazide
Form Tablet (Fixed-dose combination)
Pharmacological Class Angiotensin II inhibitors with thiazides
Common Use Treatment of Essential Hypertension
Origin Synthetic Pharmaceutical Compound

What is Olmesar-H and Its Purpose?

Olmesar-H is a prescription-only, fixed-dose combination product specifically manufactured for the oral treatment of essential hypertension (high blood pressure). This medication is clinically recognized for its effectiveness in achieving and maintaining target blood pressure goals when a single medication is insufficient. The drug is a synthetic compound supplied as a tablet, ensuring a single, comprehensive delivery of two distinct therapeutic agents. This approach, combining agents with complementary functions, is an established clinical strategy for patients needing multi-modal blood pressure control.


The Composition and Pharmacological Class of Olmesar-H

The drug's structure is defined by its two core active ingredients: Olmesartan Medoxomil and Hydrochlorothiazide. This blend places Olmesar-H into the combined antihypertensive classification known as Angiotensin II inhibitors with thiazides.

  • Olmesartan Medoxomil is an Angiotensin II Receptor Blocker (ARB), a class of medication that works by blocking the action of a substance that normally causes blood vessels to tighten. This component helps blood vessels relax and widen, enabling smoother blood flow.
  • Hydrochlorothiazide is a thiazide diuretic (often called a water pill), which supports the cardiovascular system by promoting the renal excretion of excess salt and water. This diuretic component lowers blood pressure by reducing the total volume of fluid circulating in the body.

How Olmesar-H Combines Two Actions

Olmesar-H reduces high blood pressure by simultaneously managing vascular constriction and excess fluid volume. This synergistic mechanism provides a rationale for combination therapy, where this pairing improves the blood pressure lowering efficacy compared with either substance used alone. The result is a robust and complementary action where vessel relaxation and fluid volume reduction work together to achieve sustained blood pressure control.

Regulatory References

  1. National Institutes of Health (NIH DailyMed)
  2. references like MedlinePlus

What side effects are possible with Olmesar-H?

Possible Side Effects and Safety Information

The safety profile of Olmesar-H (Olmesartan Medoxomil and Hydrochlorothiazide) is formally structured by regulatory authorities to classify and communicate documented adverse reactions. These effects are categorized primarily by frequency and the body system affected, based on data from controlled clinical trials and postmarketing surveillance.

Frequency-Classified and Systemic Effects

Adverse reactions reported as Common (occurring in 1% to 10% of patients in trials) include dizziness, headache, nausea, upper respiratory tract infection, and hyperuricemia (elevated uric acid levels in the blood). The officially documented effects span several System-Organ Classes, notably affecting the Nervous System (dizziness, headache) and Metabolism and Nutrition (hyperuricemia, electrolyte imbalances).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions. These include Angioedema (swelling of the face, lips, or throat) and a rare gastrointestinal event known as Sprue-like enteropathy, which is characterized by severe, chronic diarrhea and may develop months to years after starting treatment. The combination is also associated with Acute Myopia and Secondary Angle-Closure Glaucoma due to the hydrochlorothiazide component.

Specific Safety Constraints and Contraindications are officially documented. Olmesar-H must not be used in individuals with Anuria (inability to urinate), known hypersensitivity to the components or sulfonamide-derived drugs, and is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity. Additionally, use is generally not recommended in patients with severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Olmesar-H (Olmesartan Medoxomil and Hydrochlorothiazide) is primarily characterized by two distinct physiological effects documented in regulatory labeling: circulatory depression and severe fluid and electrolyte imbalance.

Documented Overdose Manifestations

Overdose may present with hypotension (low blood pressure) and corresponding compensatory signs such as tachycardia (fast heart rate). In some cases, bradycardia (slow heart rate) may be encountered. Signs related to the Hydrochlorothiazide component include acute volume loss, dehydration, and electrolyte depletion, specifically hypokalemia and hypochloremia.

Required Emergency Actions

Immediate medical attention is required for any manifestation of overdose, particularly if symptomatic hypotension or severe volume loss occurs. The regulatory documentation mandates that if hypotension develops, supportive treatment must be initiated, including placing the patient in the supine position. Management often includes restoring fluid volume through an intravenous infusion of normal saline.

Treatment is entirely symptomatic and supportive. There is no specific antidote known for Olmesar-H overdose, and the dialyzability of olmesartan is unknown. For neonates with a history of in utero exposure, if hypotension or oliguria occurs, support of blood pressure and renal perfusion may require measures such as exchange transfusions or dialysis.

Therapeutic Uses of Olmesar-H

What Olmesar-H Treats: Main Uses and Benefits

Olmesar-H is generally prescribed for the long-term management of essential hypertension (chronic high blood pressure), addressing the pathological state of persistently elevated systemic pressure. This therapeutic approach is used to support the achievement and maintenance of target blood pressure levels, contributing to supportive care for the cardiovascular system over time. The primary therapeutic use is in conditions characterized by chronic, sustained high blood pressure, particularly in cases of Stage 2 hypertension or when single-agent treatments have been insufficient.

This medication may assist with the proactive mitigation of long-term cardiovascular risk factors. It is applied in situations where patients experience noticeable physiological strain, such as when blood pressure remains uncontrolled despite monotherapy. The medication is associated with mitigating the risk of severe complications, including stroke, heart attack, and progressive kidney disease, and may assist with maintaining functional stability.


Quick Fact: Relief for Systemic Strain
Primary Use: Management of Essential Hypertension
Goal Benefit: Mitigating Cardiovascular Risk Factors
Scenario: When Monotherapy is Insufficient

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Olmesar-H?

Eligibility for Olmesar-H (olmesartan medoxomil and hydrochlorothiazide) is strictly defined by government regulatory documents and is limited to specific patient populations. This medication is generally intended for adults with essential hypertension whose blood pressure remains uncontrolled when taking a single agent.


Populations Where Use is Prohibited (Contraindicated)

Contraindication Basis for Restriction
Pregnancy Absolute prohibition during the second and third trimesters.
Anuria Prohibition due to the hydrochlorothiazide (diuretic) component.
Diabetes Mellitus Prohibited if concurrently taking aliskiren-containing products.
Hypersensitivity Prohibited for patients allergic to the drug components or sulfonamide-derived drugs.

Age and Condition Restrictions

  • Pediatric Use: The medication is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.
  • Organ Impairment: Use is contraindicated or not recommended for patients with severe renal impairment (e.g., creatinine clearance leq 30 mL/min) or severe hepatic impairment (based on European labeling).
  • Lactation: Use is not recommended; a patient must decide whether to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Olmesar-H (olmesartan medoxomil and hydrochlorothiazide) has documented interactions that require careful management, primarily related to its effect on the renin-angiotensin-aldosterone system (olmesartan) and electrolyte balance (hydrochlorothiazide).

Interacting Product Category Key Interaction Risk Regulatory Status
Aliskiren Increased risk of severe hypotension, hyperkalemia, and worsening renal function. Contraindicated in patients with diabetes.
Potassium-Sparing Diuretics (e.g., spironolactone), Potassium Supplements Increased risk of elevated serum potassium (hyperkalemia). Use with caution and monitor.
NSAIDs (e.g., selective COX-2 inhibitors) May reduce the antihypertensive and diuretic effects; increased risk of renal function deterioration. Use with caution, especially in volume-depleted or elderly patients.
Lithium Thiazides reduce lithium's renal clearance, significantly increasing the risk of lithium toxicity. Generally not recommended. Monitor lithium levels closely if co-administered.
Colesevelam hydrochloride Reduces the absorption of olmesartan. To minimize interaction, take Olmesar-H at least 4 hours prior to colesevelam.
Cholestyramine and Colestipol Reduced absorption of the hydrochlorothiazide component. Take Olmesar-H 4 hours before or 4 to 6 hours after the bile acid sequestrant.

Other medicines that may potentiate orthostatic hypotension when combined with the hydrochlorothiazide component include alcohol, barbiturates, or narcotics. Dosage adjustments may be necessary for antidiabetic drugs (oral agents and insulin), as hydrochlorothiazide can affect blood glucose control.

Mechanism of Action

Biological Mechanism of Action

Olmesar-H functions via two distinct, complementary mechanisms. The Olmesartan component is a specific, competitive antagonist of the Angiotensin II type 1 (AT1) receptor . Binding to the AT1 receptor prevents Angiotensin II from triggering its signaling cascade, which results in the reduction of systemic vascular resistance and subsequent vasodilation.

Concurrently, Hydrochlorothiazide (HCTZ) acts as an inhibitor of the sodium-chloride cotransporter (NCC) in the distal convoluted tubules of the kidney. This action diminishes Na^+ and Cl^- reabsorption, leading to increased excretion of water and ions. The physiological consequence of NCC inhibition is a reduction in total circulating fluid volume.

The combined action provides dual-pathway modulation that influences both vascular tone and fluid balance. Furthermore, the AT1 receptor blockade mitigates the compensatory RAAS activation that may occur secondary to fluid volume reduction, ensuring simultaneous control of both systemic resistance and circulating volume.

Dosage and Administration Information

The fixed-dose combination Olmesar-H is prescribed exclusively for oral administration as a film-coated tablet, to be taken once daily. The tablet should be swallowed whole with fluid and should not be chewed. The medication may be taken either with or without food, as food does not impact the absorption of the active components.


Official Dosing and Titration Protocol

The combination product is not indicated for the initial treatment of high blood pressure, but rather for patients whose condition is not adequately controlled by monotherapy. Official starting doses are typically set at either 20 mg/12.5 mg or 40 mg/12.5 mg (Olmesartan/Hydrochlorothiazide) once daily, depending on the patient's previous regimen. Dosages are subject to adjustment (titration) after an initial period of two to four weeks of consistent therapy, as deemed necessary, with the maximum recommended daily dose reaching 40 mg/25 mg.


Administration Context and Restrictions

While no initial dose adjustment is required for older adults, the label places restrictions on use in specific populations. Use is contraindicated in patients with severe renal impairment (creatinine clearance le 30 mL/min) or severe hepatic impairment. Furthermore, specific scheduling instructions apply when the drug is co-administered with certain bile acid sequestrants; for instance, Olmesar-H should be taken at least four hours before colesevelam hydrochloride.

Recent Clinical Evidence

Research Evidence for Use in Essential Hypertension

Research on Olmesar-H primarily focuses on how the fixed-dose combination drug was evaluated. Researchers utilized short-term, randomized, controlled, double-blind trials with a factorial design to compare the combination treatment with its individual components and with an inactive placebo. Studies measured changes in Systolic (SBP) and Diastolic (DBP) blood pressure from baseline, and explored the number of participants who achieved pre-defined blood pressure targets. Studies recorded patterns of measured outcomes when comparing combination treatment with single drug components and placebo.


Comparative Evidence and Use When Monotherapy is Insufficient

Olmesar-H was studied in the context where participants' blood pressure was not yet reduced to target levels with monotherapy. The research explored participants with Stage 2 Hypertension and those whose blood pressure was not yet reduced to target levels with monotherapy. Studies performed measurements when comparing the outcomes of using the combination drug with single drug components. The studies described patterns of participants reaching blood pressure control goals when the combination was evaluated in cases where monotherapy was assessed as insufficient.


Assessment of Long-term Outcomes and Follow-up

Although primary trials to confirm blood pressure measurement had a relatively short duration (generally 8 to 12 weeks), additional data provided insight into continuous monitoring of control. Long-term outcome assessments explored major cardiovascular events (e.g., stroke or heart attack). The evaluation of long-term outcomes is primarily based on data from the general antihypertensive drug class, which is consistent with maintaining acceptable blood pressure levels. There are no large, dedicated, randomized trials specifically designed to assess the direct impact of Olmesar-H on measuring the rate of death or cardiovascular events in the long term.


Limitations of Existing Evidence and Uncertainty

A key limitation is the lack of direct long-term data from trials focused on cardiovascular outcomes specifically for this combination formula. Data remains insufficient for a clear conclusion on the consistency of outcomes across all subgroups. The varied findings in specific high-risk group studies using Olmesartan monotherapy indicate that the understanding of potential benefit and risk in those populations remains nuanced and is a subject requiring careful consideration.

Frequently Asked Questions (FAQ)

Common questions about Olmesar-H (FAQ)


Q: How quickly should I expect Olmesar-H to start lowering my blood pressure?

While the medication is prescribed for once-daily use, the full blood pressure-lowering effect may take several weeks to become fully apparent. Official product information indicates that healthcare providers typically assess the need for a dose adjustment after two to four weeks of consistent therapy for monitoring of the drug's effect.


Q: Can older adults take Olmesar-H?

Older adults (generally 65 years of age and older) may be prescribed Olmesar-H, and official information confirms that no initial dose adjustment is usually required based on age alone. However, usage is subject to general contraindications, such as avoidance in cases of severe kidney impairment.


Q: Is feeling more tired than usual a known side effect of Olmesar-H?

Official regulatory documents indicate that fatigue (feeling tired) is one of the common adverse reactions reported in clinical trials. Patients are advised to discuss any side effects with their healthcare provider.


Q: Are there certain foods or supplements I should avoid while taking Olmesar-H?

Caution is advised when using supplements that contain potassium or medications called Potassium-sparing diuretics, as combining them with Olmesar-H increases the risk of high potassium levels (hyperkalemia). The medication itself can be taken with or without food.


Q: What kind of kidney monitoring is required when taking Olmesar-H?

Since the medication is contraindicated (should not be used) in severe kidney impairment, the need for kidney function monitoring is often required due to the drug's potential effects on renal function. Monitoring is particularly important when taken alongside other drugs, like NSAIDs, which can increase the risk of renal function deterioration.


Q: Why might a doctor switch a patient from another medication to Olmesar-H?

According to official documentation, this combination product is indicated for patients whose high blood pressure is not adequately controlled when they are taking a single-ingredient blood pressure medication (monotherapy). The fixed-dose combination is recognized for its dual-action approach, which may provide more comprehensive control.


Q: Is it OK to crush or split Olmesar-H tablets?

Official guidance states that the tablet should be swallowed whole with fluid. The tablet is not meant to be chewed or otherwise altered, such as by crushing or splitting, before swallowing.


Q: What should I do if my blood pressure remains high while taking Olmesar-H?

Official protocols indicate that dosages are subject to adjustment, or titration, by a healthcare provider if blood pressure goals are not met. This adjustment period usually takes place after two to four weeks of consistent therapy.


Q: Is Olmesar-H a blood pressure medicine or something else?

Olmesar-H is classified as a prescription-only, fixed-dose combination product specifically indicated for the treatment of essential hypertension, which is the medical term for high blood pressure.


Q: Is it normal to feel dizzy when first starting Olmesar-H?

Dizziness is officially documented as a Common adverse reaction, meaning it occurred in 1% to 10% of patients during clinical trials. This is a recognized potential effect of the medication.


Q: How often do people usually take Olmesar-H?

The medication is intended for use as a single tablet taken once daily (every 24 hours). This administration schedule is designed for the management of high blood pressure.


Q: Are there common signs that Olmesar-H is working correctly?

Effectiveness is clinically measured by the reduction in Systolic and Diastolic blood pressure (SBP and DBP). Consistent blood pressure readings within target goals are typically monitored during treatment.


Q: Does Olmesar-H interact with common pain relievers like ibuprofen?

Regulatory documents note that NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which include ibuprofen, may reduce the blood pressure-lowering and diuretic effects of the medication. They can also increase the risk of renal function deterioration.


Q: How long does the effect of one dose of Olmesar-H last?

The product is prescribed to be taken once daily, indicating its blood pressure-lowering effect is intended to last for a full 24-hour period between doses.


Q: Do people on Olmesar-H typically need to take it forever?

The medication is used to manage essential hypertension, a chronic condition that often requires long-term therapy to maintain acceptable blood pressure levels and reduce cardiovascular risk.


Q: Can Olmesar-H affect sleep or cause insomnia?

Yes, official adverse event listings indicate that insomnia (difficulty sleeping) has been reported as an adverse reaction associated with the hydrochlorothiazide component of the drug.


Q: What are some less common but serious side effects of Olmesar-H to watch out for?

Official safety constraints highlight several serious adverse reactions, including Angioedema (swelling of the face, lips, or throat), a rare intestinal condition called Sprue-like enteropathy, Acute Myopia, and a form of sudden eye pressure increase called Secondary Angle-Closure Glaucoma.


Q: Can Olmesar-H affect blood sugar readings?

Yes, the hydrochlorothiazide component can affect blood glucose control. Official prescribing information indicates that dosage adjustments may be necessary for people taking antidiabetic drugs (both oral agents and insulin).


Q: Is it safe to drive or operate machinery while on Olmesar-H?

Patients should be aware that symptoms like dizziness or fatigue may occur, which could impair the ability to drive or operate machinery. This risk is noted, especially when starting treatment or during dose changes.


Q: Does the time of day I take Olmesar-H matter for its effectiveness?

The medication can be taken with or without food. While it is a once-daily drug, some clinical observations indicate that the timing of the dose may be adjusted based on individual blood pressure patterns.


Q: How should Olmesar-H be stored?

The tablets must be stored at Controlled Room Temperature (typically 20°C to 25°C), kept in the original container, and maintained tightly closed. This is to protect the medicine from excess heat and moisture.


Q: Are there situations where Olmesar-H is not effective for blood pressure?

The drug is not indicated for the initial treatment of high blood pressure. Its use is reserved for patients whose condition is not adequately controlled when taking a single blood pressure medication.


Q: What is the average duration before a doctor adjusts the dose of Olmesar-H?

According to the official dosing protocol, dosages are subject to adjustment (titration) after an initial period of two to four weeks of consistent therapy. This duration allows the healthcare provider to assess the full response.


Q: Can Olmesar-H be used by people with mild liver impairment?

Use is strictly prohibited (contraindicated) in cases of severe hepatic impairment. Use in patients with mild-to-moderate liver impairment is generally done with caution, but it is not listed as an absolute prohibition.


Q: Does Olmesar-H make you urinate more often?

Yes, the Hydrochlorothiazide component is a diuretic (a 'water pill'), and its intended action is to increase the excretion of water and ions from the kidneys, which can lead to increased urination.


Q: What does clinical research say about the benefits of Olmesar-H?

Studies confirmed that the combination treatment was effective in achieving greater blood pressure reduction (in both SBP and DBP) compared to the individual components alone. The research measured how many participants achieved pre-defined blood pressure targets with the combination.

How should Olmesar-H be stored and disposed of?

Storage Conditions

Olmesar-H tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in the original container and maintained tightly closed to protect it from excess heat and moisture. It is mandatory to keep this medicine out of the reach of children and in a location out of their sight.


Disposal Instructions

Unused or expired Olmesar-H should be disposed of following official regulatory protocols. The most recommended method is to use a drug take-back program available at pharmacies or collection sites. If a take-back program is unavailable, the tablets may be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. The tablets must not be crushed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olmesar-H found in:

A-Z Index: